LGALS3 and type 2 diabetes mellitus: In contrast, in T2DM patients, galectin-3 was the only biomarker associated with an increase of the incidence of this outcome (HR 1.83 (1.13–2.98), p = 0.014), along with previous history of cerebrovascular events (HR 12.4 (2.16–71.1), p = 0.005).